Skip to main content

Table 2 The baseline characteristics in subjects with and without habitual exercise and hyperglycemia

From: The joint impact of habitual exercise and glycemic control on the incidence of chronic kidney disease (CKD) in middle-aged and older males

 

Habitual exercise

p value

Presence/absence of hyperglycemia

p value

Yes (n = 148)

No (n = 155)

NGT (n = 255)

Hyperglycemia (n = 48)

eGFR (ml/min/1.73 m2)

77.3 ± 10.5

76.7 ± 10.2

0.583

76.0 ± 9.5

77.2 ± 10.5

0.495

Classifications of CKD grade

 G1 (n, %; eGFR ≥ 90 ml/min/1.73 m2)

12 (8.1)

17 (11.0)

0.396

26 (10.2)

3 (6.3)

0.348

 G2 (n, %; eGFR 60–89 ml/min/1.73 m2)

136 (91.9)

138 (89.0)

 

229 (89.8)

45 (93.7)

 

Serum creatinine (mg/dl)

0.83 ± 0.10

0.85 ± 0.09

0.225

0.83 ± 0.09

0.84 ± 0.10

0.583

Age (years)

52.1 ± 6.5

52.3 ± 6.8

0.887

51.5 ± 6.7

55.6 ± 5.9

< 0.0001

Body weight (kg)

66.8 ± 9.9

68.4 ± 8.8

0.176

67.1 ± 9.1

69.5 ± 10.0

0.099

BMI (kg/m2)

23.1 ± 2.6

23.7 ± 2.8

0.094

23.3 ± 2.2

24.2 ± 2.6

0.137

Waist circumference (cm)

81.1 ± 8.0

85.4 ± 7.1

0.086

82.3 ± 7.5

85.6 ± 7.9

0.166

SBP (mmHg)

125.1 ± 15.6

129.6 ± 14.7

0.041

125.3 ± 14.6

134.2 ± 17.3

0.002

DBP (mmHg)

81.6 ± 10.4

83.8 ± 10.4

0.753

82.1 ± 10.2

85.9 ± 11.2

0.048

LDL-C (mg/dl)

117.0 ± 26.3

119.7 ± 24.1

0.346

118.9 ± 25.3

116.0 ± 24.5

0.456

HDL-C (mg/dl)

60.3 ± 13.2

56.1 ± 13.1

0.005

59.7 ± 13.1

54.3 ± 14.3

0.009

Triglyceride (mg/dl)

111.8 ± 69.1

117.9 ± 70.6

0.452

110.4 ± 67.9

138.2 ± 75.3

0.010

Fasting glucose (mg/dl)

97.8 ± 14.9

104.2 ± 20.8

0.146

95.0 ± 7.7

128.3 ± 27.9

< 0.0001

HbA1c (NGSP values; %)

5.5 ± 0.6

5.8 ± 0.8

0.036

5.4 ± 0.4

6.4 ± 1.3

< 0.0001

HbA1c (IFCC values; %)

35.5 ± 6.8

40.4 ± 8.4

0.031

36.3 ± 3.9

46.6 ± 13.9

< 0.0001

Smoking habit (yes/no; n, %)

30 (20.3)/118 (79.7)

33 (21.3)/122 (78.7)

0.827

56 (22.0)/199 (78.0)

7 (14.6)/41 (85.4)

0.195

Drinking habit (yes/no; n, %)

119 (80.4)/29 (19.6)

113 (72.9)/42 (27.1)

0.123

192 (75.3)/63 (24.7)

40 (83.3)/8 (16.7)

0.531

Anti-hypertensive drugs (yes/no; n, %)

19 (12.8)/129 (87.2)

24 (15.5)/131 (84.5)

0.509

29 (11.4)/226 (88.6)

14 (29.2)/34 (70.8)

0.002

Anti-hyperlipidemic agents (yes/no; n, %)

17 (11.5)/131 (88.5)

8 (5.2)/147 (94.8)

0.046

19 (7.5)/236 (92.5)

6 (12.5)/42 (87.5)

0.292

Hypoglycemic drugs (yes/no; n, %)

2 (1.4)/146 (98.6)

5 (3.2)/150 (96.8)

0.278

0 (0)/255 (100)

7 (14.6)/41 (85.4)

< 0.0001

  1. The data are expressed as the mean ± standard deviation and the number of subjects
  2. The abbreviations are the same as those in Table 1
Back to article page

Environmental Health and Preventive Medicine

ISSN: 1347-4715

Contact us